Nova Eye Grew 30% and Turned Cash-Positive — Then Chose Not to Raise Guidance
The quarter that accelerated — and the number they left alone
Nova Eye Medical is a tiny Adelaide-based device company selling a single idea into a single market: a tissue-sparing, implant-free canaloplasty catheter that unblocks the eye's natural drainage instead of stenting it or cutting it. In the September quarter it booked sales of US$6.3m, up 30% year-on-year, lifting trailing-twelve-month revenue to US$25.1m — also up 30% — against the US$23.6m booked for the June year. It generated US$0.5m of operating cash flow and, management says, positive EBITDA. None of these are round numbers of convenience; they are the reported figures.
What makes the quarter worth reading is what it says about the shape of the growth curve. CEO Thomas Spurling has spent years selling a four-year 26% compound annual growth rate, and the rate of growth is now the top-ranked theme on this call for the first time — not because the company grew, but because it claims to be growing faster than the market it sells into, citing independent Market Scope tracings of US stand-alone glaucoma surgery. Management framed that as “a very good stage, growth stage ophthalmology company... We are just selling stuff, and we're doing well.” — Thomas Spurling, CEO · 2026-11-01 The growth-stage ophthalmology framing is doing real work here: it pre-empts the two questions this name has historically been asked — what trials are you running, and when do you run out of money.
The answer to the second is: not yet, but the margin is thin. Cash plus undrawn debt sits at US$4.1m, up US$0.5m since 30 June, against a market capitalisation of roughly US$27m. Spurling is unapologetic: “We are guiding to sustainable positive cash flow. Cash is lumpy.” — Thomas Spurling, CEO · 2026-11-01 The positive cash flow and positive EBITDA beats are the substance of the quarter; the balance sheet is a constraint, not a cushion.
The guidance that wasn't raised
Guidance was confirmed — not lifted — at US$26m to US$31m, excluding China. That is a deliberately wide band for a company that just printed 30% growth and, according to the CEO, saw October US sales tracking above 30%. Asked directly why he would not take the number up after a strong quarter, Spurling answered:
Just because I'm gutless. I think we want to hit our guidance. We're obviously confident and shareholders can form their own view.
It is a disarming line, and it is also a tell. Across the last year management has consistently talked in terms of an achievable "20% plus" growth target with an EBITDA-positive bottom line; a 30% quarter is now the second consecutive acceleration, which makes the held guidance look conservative rather than bold. The company is choosing to bank credibility rather than stretch it — a defensible posture for a name whose prior pitch was trust. “Top line growth is probably the easiest one to do, but we are doing it in a way to make sure we don't destroy our bottom line.” — Thomas Spurling, CEO · 2026-11-01
A share-gain story told against a stalled incumbent
The most useful competitive datapoint on the call was about someone else. Of Glaukos, the market leader, Spurling observed that “their stent revenue has stalled at about $40 million a quarter for about the last 5, 6 quarters in a row” — Thomas Spurling, CEO · 2026-11-01 while that company pivots toward iDose, a procedural pharmaceutical that does not directly compete. Glaukos has been a recurring rhetorical foil for Nova Eye — it was a top-spiking theme back in the June 2026 quarter — but the framing has shifted from "we ride their coattails" to "their flagship number is flat and ours is not."
Nova Eye now claims 4% to 5% US market share. In February it told investors 3.5% to 3.9%: “3.5%, 3.9% isn't very much.” — Thomas Spurling, Managing Director and CEO · 2026-02-01 A share point of movement on a small base is not proof of anything, but it is the only hard directional evidence the company gives on penetration, and it points the right way. The interventional glaucoma thesis — treat surgically and early, off drops — remains company-unique in this data set: none of the top-75 market keywords for the quarter, and none of the recent healthcare reporters, are discussing glaucoma outflow at all. That is both the opportunity (no crowded trade) and the risk (no sector tailwind, no peer validation, no tape).
The change nobody asked about: the currency
Buried near the end of the prepared remarks is the most structurally consequential item in the report. More than 90% of revenue is invoiced in US dollars and 85% of operating costs are in US dollars, so from 31 December Nova Eye will report in USD rather than AUD. Spurling's jab is aimed at analysts who mechanically translated a USD guidance raise into a lower AUD revenue line. This matters beyond cosmetics: the company is formally re-designating itself as a dollar business listed in Australia, which pairs awkwardly with shareholders who keep asking about a dual listing-adjacent question every single call — a NASDAQ listing, which management deflected with "we're a little company at the moment," and the perennial Australian market query about why the product isn't reimbursed at home. Both are repeats.
What is new is the investor-education layer. This quarter's keyword set introduces ocular irrigation system and the mechanics of pressure build-up as top-three themes — a physiological explainer aimed at generalists, not surgeons. Meanwhile revenue per rep, which ranked in the top handful of keywords in three of the last four quarters, has dropped out of the top-30 entirely, even as Spurling grumbled about disclosing it because competitors thank him for the data. The metric that used to carry the story has been demoted; the growth rate and the mechanism of action now carry it. Whether that is a deliberate pivot or simply a quarter where the calculator was left in the bag is hard to say — but the prior calls were candid that rep additions cause a productive dip: “when we put on more reps, there must be a dip naturally because you can't get all those sales in the first month the person is there.” — Thomas Spurling, Chief Executive Officer · 2026-05-05
What the report does not settle
Three things. First, China: a delivery to China rounded the quarter to US$6.3m from US$5.2m US plus Rest of World, but guidance explicitly excludes it and management will not forecast it. The headline growth rate therefore flatters or penalises on a lumpy, non-recurring shipment. Second, reimbursement: the CPT 1 code rates for calendar 2027 are proposed at the same level as 2026 and are typically finalised in November — a genuine near-term catalyst, and a binary one, though the company treats it as a formality. Third, seasonality: management notes that July and August surgery volumes sag and that the December quarter is the big season, with October's US run-rate above 30% offered as a pre-announcement of sorts. That is the quarter to test the whole thesis against.
For a company this size, with implant-free canaloplasty as its differentiating claim and a cash balance measured in months of runway rather than years, the story is unusually clean and unusually fragile at once. A 30% quarter, positive cash generation, and a self-imposed ceiling on expectations is a combination worth watching — not because the guidance was conservative, but because management chose to be.